Loading…
← CockpitCompetitor Analysis › 002907.SZ Chongqing Pharscin Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Chongqing Pharscin Pharmaceutical Co., Ltd. Class A002907.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum strong 63
Mkt cap
$752M
US dollars, full cap
Free float
31%
of shares outstanding
$/day
$15.9M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+4.8 pp
WACC 5.0%
Hurdle
+11 pp
Req g minus delivered
Close · CNYCN¥12.15
1D-2.7%
1W-10.0%
1M-20.4%
3M-12.4%
6M-6.8%
YTD-18.0%
1Y-25.1%
ATR %5.0%
52w lowhigh34.2% off high

What Chongqing Pharscin Pharmaceutical does

Employees: 1,439

Chongqing Pharscin Pharmaceutical at a glance

Size Chongqing Pharscin Pharmaceutical (002907.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $752M, the 2722nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥12.15 on 18 Nov 2026.

Performance Over six months the shares fell 6.8%, against -20.1% for the median peer and -20.0% for the China market (cap-weighted) — 6th highest of 19 in its peer set.

Growth Revenue grew 8.5% over the last twelve months (peer median +2.4%); the operating margin is 9.7% (peer median 8.8%).

Valuation It trades at 5.3× enterprise value to sales against a peer median of 2.5× (5th most expensive of 18).

Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +11 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 4.8 points above its cost of capital (5.0% WACC).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026002907.SZ 94Peer median 81
Six months, rebased to 100: Chongqing Pharscin Pharmaceutical against the median of its 20 peers (local-currency closes).

Chongqing Pharscin Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥839MCN¥814MCN¥763MCN¥681MCN¥773M
Revenue growth—+7%+12%-12%—
Gross profitCN¥509MCN¥426MCN¥402MCN¥344MCN¥440M
EBITDAn/aCN¥141MCN¥148MCN¥110MCN¥170M
Net incomeCN¥93.8MCN¥65.1MCN¥76.7MCN¥32.7MCN¥98.4M
Free cash flowCN¥89.7MCN¥53.5MCN¥149MCN¥127M-CN¥44.3M
Capital expenditureCN¥35.7MCN¥14.6MCN¥16.2MCN¥92.8MCN¥60.6M
Total debtCN¥2.86MCN¥41.8MCN¥127,562CN¥281,958CN¥169,881

Quarterly statements and history in the cockpit →

Chongqing Pharscin Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-25%0%+25%+50%21710024246004793001LXRX2186002390BLISSGVS600530688799000411SGMTARDX002349002907.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Chongqing Pharscin Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%0×10×20×30×21710024246004793001LXRX2186002390BLISSGVS688566600530ARDX6039980570002907.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Chongqing Pharscin Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%00242460047930013007052186002390BLISSGVS688566600530603998002907.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Chongqing Pharscin Pharmaceutical is the large dot.

Chongqing Pharscin Pharmaceutical competitors and peer comparison

How Chongqing Pharscin Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Chongqing Pharscin Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure002907.SZPeer medianRank in peer set
1-month return-20.4%-5.2%lowest of 19
6-month return-6.8%-20.1%6th highest of 19
Distance from 52-week high-34.2%-34.6%10th highest of 19
Revenue growth (TTM)+8.5%+2.4%5th highest of 19
Operating margin9.7%8.8%9th highest of 19
EV / Sales5.3×2.5×5th most expensive of 18
Growth the price implies (Req g, 7 yrs)9.4%-2.0%4th most demanding of 12
Growth delivered (Del g)-1.4%+1.9%lowest of 12
Hurdle (Req g minus delivered)+10.7 pp-3.1 pp4th most demanding of 12
ROIC minus cost of capital+4.8 pp-0.3 pp3rd highest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Chongqing Pharscin Pharmaceutical 002907.SZChina$752M-7%+8%10%5.3×9.4%-1.4%
CARsgen Therapeutics 2171.HKHong Kong$751M-45%+68%-170%28.6×n/an/a
Guizhou Bailing Group Pharmaceutical 002424.SZChina$755M-20%-25%2%2.5×13.5%-0.2%
Zhuzhou Qianjin Pharmaceutical 600479.SSChina$746M-3%+4%11%1.4×-2.1%0.0%
Katakura Industries 3001.TJapan$765M+40%-2%15%2.4×0.3%+0.5%
Lexicon Pharmaceuticals LXRXUnited States$766M-22%-46%-147%16.7×n/an/a
Hunan Jiudian Pharmaceutical 300705.SZChina$738M-20%-5%13%1.8×-2.0%+26.1%
Luye Pharma 2186.HKHong Kong$736M-32%+3%18%1.1×-11.8%+1.9%
Guizhou Xinbang Pharmaceutical 002390.SZChina$771M-7%-13%4%0.9×-3.8%-0.8%
Bliss GVS Pharma BLISSGVS.NSIndia$777M+141%+25%18%6.7×33.9%+10.1%
Jiangsu Jibeier Pharmaceutical 688566.SSChina$727M-9%+8%26%3.8×5.9%+11.3%
Shanghai Jiaoda Onlly 600530.SSChina$726M-25%-2%-2%16.1×42.7%-0.9%
Sichuan Neautus Traditional Chinese 2206.HKHong Kong$779Mn/a+7%8%n/an/an/a
Hunan Warrant Pharmaceutical 688799.SSChina$725M-34%-3%9%3.9×n/an/a
Zhejiang Int'l 000411.SZChina$783M-21%+3%3%0.3×n/an/a
Sagimet Biosciences SGMTUnited States$722M+52%n/an/an/an/an/a
Ardelyx ARDXUnited States$784M-50%+18%-8%1.6×n/an/a
Jinghua Pharmaceutical 002349.SZChina$785M-8%+2%20%3.1×-2.5%+2.6%
Hunan Fangsheng Pharmaceutical 603998.SSChina$719M-1%+12%20%2.6×-4.8%+6.4%
China Traditional Chinese Medicine 0570.HKHong Kong$716M-31%-16%0%0.3×n/an/a
Bambusa Therapeutics BBTXUnited States$791Mn/an/an/an/an/an/a

Questions

Which companies are Chongqing Pharscin Pharmaceutical's closest peers?
The cockpit's peer set: CARsgen Therapeutics (2171.HK), Guizhou Bailing Group Pharmaceutical (002424.SZ), Zhuzhou Qianjin Pharmaceutical (600479.SS), Katakura Industries (3001.T), Lexicon Pharmaceuticals (LXRX), Hunan Jiudian Pharmaceutical (300705.SZ), Luye Pharma (2186.HK), Guizhou Xinbang Pharmaceutical (002390.SZ).
Is Chongqing Pharscin Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 5.3× against a peer median of 2.5×, 5th most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +11 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Chongqing Pharscin Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -6.8% against -20.1% for the median peer; over one year -25.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.